{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:34:28Z","timestamp":1770060868632,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T00:00:00Z","timestamp":1299110400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10549-011-1417-2","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T09:17:48Z","timestamp":1299057468000},"page":"841-844","source":"Crossref","is-referenced-by-count":58,"title":["Complete response in HER2+\u00a0leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab"],"prefix":"10.1007","volume":"127","author":[{"given":"Mafalda","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Braga","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Lu\u00eds","family":"Passos-Coelho","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Oliveira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,3,3]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103\u2013119","journal-title":"Cancer Treat Rev"},{"key":"1417_CR2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","volume":"17","author":"BC Pestalozzi","year":"2006","unstructured":"Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935\u2013944","journal-title":"Ann Oncol"},{"key":"1417_CR3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11060-008-9768-1","volume":"93","author":"FC Bidard","year":"2009","unstructured":"Bidard FC, Guilhaume MN, Gauthier H, Cottu PH, Dieras V, Pierga JY (2009) Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 93:287\u2013288","journal-title":"J Neurooncol"},{"key":"1417_CR4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"1417_CR5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.24735","volume":"116","author":"K Yonemori","year":"2010","unstructured":"Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer. Cancer 116:302\u2013308","journal-title":"Cancer"},{"key":"1417_CR6","first-page":"4744","volume":"61","author":"MA Molina","year":"2001","unstructured":"Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744\u20134749","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"1417_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.11-90001-4","volume":"11","author":"J Baselga","year":"2006","unstructured":"Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11(Suppl 1):4\u201312","journal-title":"Oncologist"},{"key":"1417_CR8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.24735","volume":"116","author":"K Yonemori","year":"2009","unstructured":"Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2009) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer. Cancer 116:302\u2013308","journal-title":"Cancer"},{"key":"1417_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier. Anticancer Drugs 18:23\u201328","journal-title":"Anticancer Drugs"},{"key":"1417_CR10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1526-8209(11)70419-0","volume":"2","author":"LR Laufman","year":"2001","unstructured":"Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:235","journal-title":"Clin Breast Cancer"},{"key":"1417_CR11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00280-008-0859-7","volume":"63","author":"M Colozza","year":"2009","unstructured":"Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, Floridi P (2009) Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 63:1157\u20131159","journal-title":"Cancer Chemother Pharmacol"},{"key":"1417_CR12","doi-asserted-by":"crossref","unstructured":"Shojima K, Suzuki E, Saito K, Sekine S, Kitagawa D, Aruga T, Saji S, Kuro K (2008) Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol 26 (May 20 suppl; abstr 1138)","DOI":"10.1200\/jco.2008.26.15_suppl.1138"},{"key":"1417_CR13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/annonc\/mdp019","volume":"20","author":"C Ferrario","year":"2009","unstructured":"Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC (2009) Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 20:792\u2013795","journal-title":"Ann Oncol"},{"key":"1417_CR14","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","volume":"19","author":"O Mir","year":"2008","unstructured":"Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978\u20131980","journal-title":"Ann Oncol"},{"key":"1417_CR15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","volume":"7","author":"C Platini","year":"2006","unstructured":"Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778\u2013780","journal-title":"Lancet Oncol"},{"key":"1417_CR16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","volume":"19","author":"HJ Stemmler","year":"2008","unstructured":"Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19:832\u2013836","journal-title":"Anticancer Drugs"},{"key":"1417_CR17","first-page":"1373","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373\u20131377","journal-title":"Oncol Rep"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1417-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1417-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1417-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T23:15:07Z","timestamp":1560035707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1417-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1417-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,3]]}}}